How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

38 results for

Emergency Pediatric Dosing 12-14 kilogram

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Emergency Pediatric Dosing 12-14 kilogram

Emergency Pediatric Dosing 12-14 kilogram Emergency Pediatric Dosing 12-14 kilogram Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 (...) Emergency Pediatric Dosing 12-14 kilogram Emergency Pediatric Dosing 12-14 kilogram Aka: Emergency Pediatric Dosing 12-14 kilogram , Broselow Yellow II. Criteria: Body habitus Age: 18-36 months Length: 84.5 to 97.5 cm Weight: 12-14 kg (mean 13 kg) III. Findings: Vital Signs (normal) : 90-150/minute : 20-30/minute Systolic : 70-110 mmHg IV. Medications: Rapid Sequence Intubation (RSI) and intubation and ventilation Induction (Sedation) 4 mg 26 mg 40 mg Paralytic 26 mg 13 mg 1.3 mg Sedation Maintenance

2018 FP Notebook

2. Emergency Pediatric Dosing over 36 kilogram

Emergency Pediatric Dosing over 36 kilogram Emergency Pediatric Dosing over 36 kilogram Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration (...) 4 Emergency Pediatric Dosing over 36 kilogram Emergency Pediatric Dosing over 36 kilogram Aka: Emergency Pediatric Dosing over 36 kilogram , Broselow Over 36 kg II. Criteria: Body habitus Age: 13 years and older Weight >36 kg III. Findings: Vital Signs (normal) : 60-120/minute : 12-18/minute Systolic : 100-130 mmHg IV. Medications: Rapid Sequence Intubation (RSI) and intubation and ventilation Pretreatment 1.5 mg/kg 3 mcg/kg Induction (Sedation) 0.3 mg/kg (most common induction agent) 1.5 mg/kg

2018 FP Notebook

3. Emergency Pediatric Dosing 12-14 kilogram

Emergency Pediatric Dosing 12-14 kilogram Emergency Pediatric Dosing 12-14 kilogram Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 (...) Emergency Pediatric Dosing 12-14 kilogram Emergency Pediatric Dosing 12-14 kilogram Aka: Emergency Pediatric Dosing 12-14 kilogram , Broselow Yellow II. Criteria: Body habitus Age: 18-36 months Length: 84.5 to 97.5 cm Weight: 12-14 kg (mean 13 kg) III. Findings: Vital Signs (normal) : 90-150/minute : 20-30/minute Systolic : 70-110 mmHg IV. Medications: Rapid Sequence Intubation (RSI) and intubation and ventilation Induction (Sedation) 4 mg 26 mg 40 mg Paralytic 26 mg 13 mg 1.3 mg Sedation Maintenance

2015 FP Notebook

4. Emergency Pediatric Dosing over 36 kilogram

Emergency Pediatric Dosing over 36 kilogram Emergency Pediatric Dosing over 36 kilogram Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration (...) 4 Emergency Pediatric Dosing over 36 kilogram Emergency Pediatric Dosing over 36 kilogram Aka: Emergency Pediatric Dosing over 36 kilogram , Broselow Over 36 kg II. Criteria: Body habitus Age: 13 years and older Weight >36 kg III. Findings: Vital Signs (normal) : 60-120/minute : 12-18/minute Systolic : 100-130 mmHg IV. Medications: Rapid Sequence Intubation (RSI) and intubation and ventilation Pretreatment 1.5 mg/kg 3 mcg/kg Induction (Sedation) 0.3 mg/kg (most common induction agent) 1.5 mg/kg

2015 FP Notebook

5. Infective Endocarditis in Childhood: 2015 Update (Full text)

, with specific attention to the disease as it affects infants and children. In particular, the impact of increased survival for children with congenital heart disease (CHD) on the epidemiology of IE is updated, and newer tools useful for diagnosis and treatment in the pediatric population are reviewed. This review emphasizes changing management perspectives and discussion of new agents that have utility for treatment of resistant organisms. In addition, proper use of the diagnostic microbiology laboratory (...) Association (AHA) published “Unique Features of Infective Endocarditis in Childhood,” which reviewed epidemiology, pathogenesis, diagnosis, clinical and laboratory findings, treatment, and prevention of infective endocarditis (IE) with particular attention to children. Since that time, other AHA reports have focused on new recommendations for treatment of IE in adults (in 2005 ) and on major changes regarding prevention of IE (in 2007 ). This document updates these issues and other concerns regarding IE

2015 American Heart Association PubMed abstract

6. Guidelines on Diabetes, Pre-Diabetes and Cardiovascular Diseases developed in collaboration with the EASD (Full text)

is not recommended for CV risk stratification. 5.1 Diabetes, pre-diabetes, and cardiovascular risk The Emerging Risk Factor Collaboration, a meta-analysis of 102 prospective studies, showed that DM in general (data on DM type were unavailable) confers a two-fold excess risk of vascular outcomes (coronary heart disease, ischaemic stroke, and vascular deaths), independent of other risk factors ( Figure ). The excess relative risk of vascular events with DM was greater in women and at younger ages. Both relative

2019 European Society of Cardiology PubMed abstract

7. Janus Kinase Inhibitors and Biosimilars for Rheumatoid Arthritis: Effectiveness and Value

of the value of this intervention. 0/14 11) Are any of the following contextual considerations important in assessing the long-term value for money at estimated pricing of upadacitinib? This intervention is intended for the care of individuals with a condition of particularly high severity in terms of impact on length of life and/or quality of life. 12/14 This intervention is intended for the care of individuals with a condition that represents a particularly high lifetime burden of illness. 12/14 Compared (...) be aware that new evidence may emerge following the publication of this report that could potentially influence the results. ICER may revisit its analyses in a formal update to this report in the future. The economic models used in ICER reports are intended to compare the clinical outcomes, expected costs, and cost effectiveness of different care pathways for broad groups of patients. Model results therefore represent average findings across patients and should not be presumed to represent the clinical

2020 California Technology Assessment Forum

8. Modulator Treatments for Cystic Fibrosis: Effectiveness and Value

. 5 ©Institute for Clinical and Economic Review, 2020 Page ES2 Evidence Report – Modulator Treatments for Cystic Fibrosis Return to Table of Contents Table ES1. FDA Approved CFTR Modulator Drugs and Their Indications Drug Dose Indication Kalydeco (Ivacaftor) 150 mg PO BID with fat containing food if 6 years and older Weight based oral dosing for younger children Patients age 6 months and older who have one mutation in the CFTR gene that is responsive to ivacaftor based on clinical and/or in vitro (...) assay data. Orkambi (Lumacaftor/ Ivacaftor) Two tablets (each containing lumacaftor 200 mg/ivacaftor 125 mg) PO q 12 hours with fat- containing food if 12 years and older Weight based oral dosing for younger children Patients age 2 years and older who are homozygous for the F508del mutation in the CFTR gene. Symdeko (Tezacaftor/ Ivacaftor) One tablet (containing tezacaftor 100 mg/ivacaftor 150 mg) PO in the morning and one tablet (containing ivacaftor 150 mg) in the evening with fat-containing food

2020 California Technology Assessment Forum

9. Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures

substantially. Studies have demonstrated that bariatric/metabolic surgery achieves superior improvements in glycemic control of patients with type 2 diabetes and obesity, compared with various medical and lifestyle interventions, and leads to substantial cost savings. Improved cardiovascular outcomes and quality of life have also been reported in patients undergoing bariatric surgery. New and emerging surgical and nonsurgical bariatric procedures are described. Criteria for bariatric procedures are better (...) fatty liver disease (NAFLD), metabolic syndrome (MetS), and many cancers, among other comorbid conditions. Obesity is now included among the global noncommunicable disease targets identified by the World DOI:10.4158/GL-2019-0406 © 2019 AACE. 13 Health Organization (WHO) (2-4). In 2015, a total of 107.7 million children and 603.7 million adults had obesity worldwide (5). The prevalence of obesity in the United States is among the highest in the world. According to the National Health and Nutrition

2019 American Association of Clinical Endocrinologists

10. Risk factors for breast cancer: A review of the evidence 2018

if they presented further information about a specific epidemiological element, such as different sub– exposures or a dose–response analysis. If there was significant overlap in included studies, then these additional meta–analyses were excluded. Overlap in studies contained within the various meta–analyses was not systematically explored for all factors. 2.4 Data extraction and synthesis After the search and study selection process, applicable full–text papers were retrieved for data extraction and analysis

2018 Cancer Australia

11. Management of Pregnancy

to foster normal and healthy development of the baby, culminating in a full-term birth. The physical, psychological, and social support that the mother receives during her pregnancy can help reduce health problems in her and the child’s life. Evidence-based care during pregnancy can have a life-long impact on both mother and baby. VA/DoD Clinical Practice Guideline for the Management of Pregnancy March 2018 Page 7 of 147 Table 1. Gestational Age at Birth Predicts Offspring Outcomes [ ] 2-5 Term (...) Gestational Age at Birth Outcomes Preterm 41 6/7 weeks Increased risk of adverse neonatal outcomes compared to full-term infants B. Epidemiology and Impact in the General Population a. Rates of Reproduction In 2014, there were 3,978,497 registered births in the United States (U.S.).[ ] In general, between 1990 and 2014, rates of reproduction in the U.S. have decreased.[ ] Women have also been giving birth at later ages. Mean age at first delivery increased from 24.9 years in 2000 to 26.3 years in 2014

2018 VA/DoD Clinical Practice Guidelines

12. Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder: A Systematic Review Update

PTSD symptoms a 21 (1,349) 12, 14, 22-40 11 (709) 22, 23, 27-29, 34-39 Reduced PTSD symptoms SMD -1.01 (95% CI, -1.28 to -0.74) SMD -1.24 (95% CI, -1.67 to -0.81) High c Loss of PTSD diagnosis 9 (474) 22-24, 31-34, 39, 41 Greater loss of PTSD diagnosis RD 0.29 (95% CI, 0.11 to 0.41) High c Depression symptoms b 15 (929) 12, 14, 22-24, 28, 29, 33, 35-40, 42 Reduced depression symptoms SMD -0.87 (-1.14 to -0.61) High c Eye movement desensitization and reprocessing PTSD symptoms a 8 (449) 13, 16, 43 (...) = 0.3233 G2 vs. G3, p = 0.5396 NR F-218 Author Year Intervention Groups Subgroup Analyzed Comorbid Condition QOL Disability/Function al Impairment Return to Work/Duty Resick et al., 2002 3 Resick et al., 2003 125 Resick et al., 2012 126 G1: CBT, CPT G2: CBT, exposure- based therapy (PE) G3: WL Exposure to Child Trauma BDI Mean (SD) No Childhood Sexual Abuse Pre-tx: 22.4 (9.5) Post-tx: 10.0 (8.3) 9 mth FU: 10.9 (9.1) Childhood Sexual Abuse Pre-tx: 24.9 (9.1) Post-tx: 11.4 (10.4) 9 mth FU: 12.9 (12.7

2018 Effective Health Care Program (AHRQ)

13. Social prescribing evidence map: technical report

and Hackney area project report did not specify intended outcomes 6 . The evaluation reports that although those who received social prescribing interventions described ‘life changing’ experiences when interviewed, there was no significant difference between those who received an intervention and the control group on measures of health, well-being, anxiety, depression, active engagement, quality of life and accident and emergency visits 6 . The GP consultation rate over the two- year life of the project (...) was higher in the intervention than in the control group. The control group were reported to have lower health status 6 . The Rotherham social prescribing project assessed impact on the demand for hospital care however, no comparison group was included in the evaluation 7, 8 . Based on a sample of those referred, the evaluation reported a reduction in inpatient admissions, in emergency department attendances and in outpatient attendances. A tool to assess well-being outcomes was developed specifically

2017 Public Health Wales Observatory Evidence Service

14. Management of Uterine Fibroids

for classification as poor quality included: no description or unclear description of randomization method (4 studies), 98,118,138,145 no report of assessment of medication adherence, 128 and failure to blind outcome assessors. 94,98 Eleven studies included a placebo or no treatment comparison group 36,65,67,74,106,118,123,128,129,147,150 . Eight studies compared two or more medications 73,84,87,102,124,133,136,149,153 and 10 compared doses of the same drug. 54,64,66,75,79,88,119,123,140,146 Several studies (...) evaluated dose schedules or regimens that change over time. Another eight studies 94,98,122,138,142,144,145,151 examined the role of an additional drug (i.e., add-back) given to decrease the side effects of the primary GnRH treatment. Six studies of medical interventions are discussed in other sections of this report: the placebo arm of two studies are discussed in the section on expectant management, because the active agents (tibolone, asoprisnil) are not approved for use in the United States; 139 103

2017 Effective Health Care Program (AHRQ)

15. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults

. Racial and Ethnic Differences in Treatment e61 10.2. Sex-Related Issues e61 10.2.1. Women e62 10.2.2. Pregnancy e62 10.3. Age-Related Issues e63 10.3.1. Older Persons e63 10.3.2. Children and Adolescents e64 11. Other Considerations e64 11.1. Resistant Hypertension e64 11.2. Hypertensive Crises—Emergencies and Urgencies e65 11.3. Cognitive Decline and Dementia e68 11.4. Sexual Dysfunction and Hypertension e69 11.5. Patients Undergoing Surgical Procedures e69 12. Strategies to Improve Hypertension (...) and Obesity e28 5.2.2. Sodium Intake e29 5.2.3. Potassium e29 5.2.4. Physical Fitness e29 5.2.5. Alcohol e29 5.3. Childhood Risk Factors and BP Tracking e31 5.4. Secondary Forms of Hypertension e32 5.4.1. Drugs and Other Substances With Potential to Impair BP Control e32 5.4.2. Primary Aldosteronism e32 5.4.3. Renal Artery Stenosis e34 5.4.4. Obstructive Sleep Apnea e34 6. Nonpharmacological Interventions e35 6.1. Strategies e35 6.2. Nonpharmacological Interventions e35 7. Patient Evaluation e38 7.1

2017 American Heart Association

16. Heart Disease and Stroke Statistics 2017 Update: A Report From the American Heart Association (Full text)

Cardiac Arrest (Chapter 18) • In the 2015 CARES (Cardiac Arrest Registry to Enhance Survival) National Survival Report for emergency medical services–treated nontrau- matic cardiac arrest, the survival rate to hospital discharge was 10.6% for adults >18 years old, 23.5% for children 13 to 18 years old, 16.6% for children >1 to 12 years old, and 6.2% for children 0. • Coronary artery calcium scores >400 versus 0 are associated with an increased risk for can- cer, chronic kidney disease, pneumonia (...) Sandeep R. Das University of Texas Southwestern Medical Center None None None None None None None Rajat Deo University of Pennsylvania NIH† None None None None Boehringer Ingelheim*; Janssen Pharmaceuticals* None Sarah D. de Ferranti Children's Hospital Boston Pediatric Heart Network, NHLBI (coPI on upcoming pediatric prevention trial)* None None None None None None James Floyd University of Washington None None None None None None None Myriam Fornage University of Texas Health Science Center

2017 American Heart Association PubMed abstract

17. European Society of Endocrinology Clinical practice guidelines for the care of girls and women with Turner syndrome

, the Pediatric Endocrine Society, the European Society for Paediatric Endocrinology, the European Society of Human Reproduction and Embryology and the Endocrine Society. These guidelines were sponsored primarily by ESE, and co-sponsored by PES, ESPE and ES. Furthermore, ESHRE, SfE, and ESC supported their own delegates for the meeting, and additional support was obtained from the AHA, the National Institute of Child Health and Human Development (NICHD grant #1R13HD089663), the National Center for Advancing (...) of Cardiology, Aarhus University Hospital, Aarhus, Denmark 4 Department of Women’s Health, University College London, London, UK 5 Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands 6 The Saban Research Institute, Children’s Hospital Los Angeles, Los Angeles, California, USA 7 Rady Children’s Hospital, University of California, San Diego, California, USA 8 Department of Pediatrics, Medical Genetics Unit, Mass General Hospital for Children, Boston, Massachusetts

2017 European Society of Endocrinology

18. Palbociclib (Ibrance) - locally advanced or metastatic breast cancer

2.3.6. Discussion on non-clinical aspects 30 2.3.7. Conclusion on the non-clinical aspects 32 2.4. Clinical aspects 32 2.4.1. Introduction 32 2.4.2. Pharmacokinetics 35 2.4.3. Pharmacodynamics 44 2.4.4. Discussion on clinical pharmacology 44 2.4.5. Conclusions on clinical pharmacology 45 2.5. Clinical efficacy 46 2.5.1. Dose response studies 46 2.5.2. Main studies 48 Analysis performed across trials (pooled analyses AND meta-analysis) 94 2.5.3. Discussion on clinical efficacy 105 2.5.4. Conclusions (...) on the clinical efficacy 108 2.6. Clinical safety 108 Study 1023 (PALOMA-3) 108 Patient exposure 109 Adverse events 109 Assessment report EMA/652627/2016 Page 3/140 Serious adverse events 113 Deaths 114 Laboratory findings 114 Safety in special populations 115 Discontinuation and dose adjustments due to AES 115 Study 1008 (PALOMA-2) – Top Line Results 117 Patient exposure 117 Adverse events 118 Serious Adverse Events 121 AEs associated with permanent discontinuation 122 Deaths 122 Patient exposure 123 Adverse

2016 European Medicines Agency - EPARs

19. Wakix - pitolisant. Narcolepsy

European Medicines Agency ESS Epworth Sleepiness Scale ESSB ESS Baseline value ESSF ESS Final value EU European Union FDA US Food and Drug Administration FUA Follow-up advice GCP Good Clinical Practice ITT Intention to Treat (population) kg Kilogram LOCF Last Observation Carried Forward mg Milligram Ml Millilitre MSLT Multiple Sleep Latency Test MWT Maintenance of Wakefulness Test ng Nanogram OR Odds Ratio PD Pharmacodynamics PDCO Paediatric Committee (European Medicines Agency) PIP Paediatric (...) on clinical pharmacology 38 2.4.5. Conclusions on clinical pharmacology 40 2.5. Clinical efficacy 40 2.5.1. Dose response studies 41 2.5.2. Main studies 43 2.5.3. Discussion on clinical efficacy 65 2.5.4. Conclusions on the clinical efficacy 67 2.6. Clinical safety 67 2.6.1. Discussion on clinical safety 77 2.6.2. Conclusions on the clinical safety 82 2.7. Risk Management Plan 82 2.8. Pharmacovigilance 95 2.9. Product information 95 2.9.1. User consultation 95 2.9.2. Labelling exemptions 95 2.9.3

2016 European Medicines Agency - EPARs

20. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting (Full text)

, the Pediatric Endocrine Society, the European Society for Paediatric Endocrinology, the European Society of Human Reproduction and Embryology and the Endocrine Society. These guidelines were sponsored primarily by ESE, and co-sponsored by PES, ESPE and ES. Furthermore, ESHRE, SfE, and ESC supported their own delegates for the meeting, and additional support was obtained from the AHA, the National Institute of Child Health and Human Development (NICHD grant #1R13HD089663), the National Center for Advancing (...) of Molecular Medicine 3 Departments of Cardiology, Aarhus University Hospital, Aarhus, Denmark 4 Department of Women’s Health, University College London, London, UK 5 Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands 6 The Saban Research Institute, Children’s Hospital Los Angeles, Los Angeles, California, USA 7 Rady Children’s Hospital, University of California, San Diego, California, USA 8 Department of Pediatrics, Medical Genetics Unit, Mass General Hospital

2016 European Society of Human Reproduction and Embryology PubMed abstract

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>